NeoVista Starts Patient Treatment in Cabernet Trial of AMD
Posted on: Friday, 30 November 2007, 09:00 CST
US-based medical device company NeoVista has treated the first European patient in the company's pivotal global clinical trial for its novel beta radiation epiretinal therapy, for the wet form of age-related macular degeneration.
The procedure was performed as part of NeoVista's Cabernet trial, which seeks to enroll a total of 450 patients (300 in the radiation treatment arm) in approximately 40 sites worldwide to evaluate the efficacy and safety of NeoVista's novel radiation therapy. Patients in the study receive a single treatment with NeoVista's targeted radiation in combination with an injection of Lucentis at the time of radiation delivery to maximize immediate effect.
Unlike the current standard of care which requires costly monthly eye injections, NeoVista's investigational therapy delivers a one-time dose of radiation providing a less invasive and potentially more cost-effective treatment option.
In addition to Germany, locations of Cabernet study sites include the UK, Spain, Switzerland, Austria, Israel, Brazil, Mexico, Peru, and the US. The Cabernet study is intended to support eventual filing for regulatory approval to market the product worldwide.
John Hendrick, president and CEO of NeoVista, said: "Ultimately, our goal is to restore vision and quality of life to elderly patients who have been stricken with this debilitating disease by liberating them of the burdens associated with existing wet AMD therapies."
Source: Datamonitor
Related Articles
- MDCT Angiography Helps Lead to Successful Treatment of Patients
- Cleveland BioLabs Doses First Patient in Radiation Injury Treatment Study
- NanoViricides and CDC Collaborate in Rabies Treatment Study
- CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina
- Data Presented at This Year's ASCO Meeting Provide New Insights into the Treatment of Patients With Myelodysplastic Syndromes
- Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
- New Treatment Guidelines Support Use of FUZEON(R) to Achieve Undetectable HIV in Treatment-Experienced Patients
- ValueOptions and Colorado Health Networks Win Administrative Services Only Contract; Social Security Administration's Mental Health Treatment Study Contract Awarded to Westat With ValueOptions and Colorado Health Networks Serving As ASO
- Drugs equivalent in angina treatment: study
- Results of Phase IIa Study Show That Reverset Has Potential to Reduce HIV Viral Load in Treatment-Experienced Patients
 |
 |
User Comments (0)
RSS Feeds